Boomerang Therapeutics

About

Boomerang Therapeutics develops a genetic device for cancer therapy. Using advanced gene editing tools, thesystem is able to effectively eliminate cancer cells by activating suicide genes. Thesystem can be potentially designed according to the genetics of each patient's tumor, paving the way to personalized treatment.

Company Intelligence Q&A

Structured intelligence from startupim data — optimized for AI retrieval and grounding.

What is the primary focus of Boomerang Therapeutics?

Boomerang Therapeutics develops a genetic device for personalized cancer therapy, utilizing advanced gene editing tools to eliminate cancer cells by activating suicide genes.

When was Boomerang Therapeutics founded?

Boomerang Therapeutics was founded in March 2015.

What is the current operational status of Boomerang Therapeutics?

Boomerang Therapeutics has been inactive since January 2017.

Where is Boomerang Therapeutics headquartered?

Boomerang Therapeutics is headquartered in Be'er Sheva, Israel.

What is the employee count of Boomerang Therapeutics?

Boomerang Therapeutics has 6 employees.

What is the current funding stage of Boomerang Therapeutics?

Boomerang Therapeutics is currently in the Pre-Funding stage, with a total raised amount of $0 USD.

Who are the founders of Boomerang Therapeutics?

The founders of Boomerang Therapeutics are Ori Zelichov and Shai Duchin.

What notable recognition did Boomerang Therapeutics receive in September 2015?

In September 2015, students from Be'er Sheva, associated with Boomerang Therapeutics, won a top prize in Boston's Genetically Engineered Machine Competition.

Sectors & technology

Primary sector

Health Tech & Life Sciences

Sub-sectors

Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development

Technologies

BiologicalsGenes

Target customers

Healthcare & Life SciencesLife SciencesPharmaceuticals

Business model

B2B

Boomerang Therapeutics — Full Company Profile (machine-readable)

Personalized Cancer Gene Therapy

About

Facts

Name	Boomerang Therapeutics
Slug	boomerang-therapeutics
Type	Israeli Startup
Founded	2015
HQ city	Be'er Sheva
HQ country	IL
Primary sector	[object Object]
Sectors	[object Object], [object Object], [object Object]
Business models	B2B
Target customers	[object Object], [object Object], [object Object]
Status	inactive
Current stage	Pre-Funding
Public stage	Pre-Funding
Total raised (USD)	0

Team (2)

Name	Role	LinkedIn
Ori Zelichov
Shai Duchin

News mentions (2)

Feb 8, 2016 — www.idtdna.com: Article
Sep 30, 2015 — www.jpost.com: Article

Intelligence Q&A

What is the primary focus of Boomerang Therapeutics?

Boomerang Therapeutics develops a genetic device for personalized cancer therapy, utilizing advanced gene editing tools to eliminate cancer cells by activating suicide genes.

When was Boomerang Therapeutics founded?

Boomerang Therapeutics was founded in March 2015.

What is the current operational status of Boomerang Therapeutics?

Boomerang Therapeutics has been inactive since January 2017.

Where is Boomerang Therapeutics headquartered?

Boomerang Therapeutics is headquartered in Be'er Sheva, Israel.

What is the employee count of Boomerang Therapeutics?

Boomerang Therapeutics has 6 employees.

What is the current funding stage of Boomerang Therapeutics?

Boomerang Therapeutics is currently in the Pre-Funding stage, with a total raised amount of $0 USD.

Who are the founders of Boomerang Therapeutics?

The founders of Boomerang Therapeutics are Ori Zelichov and Shai Duchin.

What notable recognition did Boomerang Therapeutics receive in September 2015?

In September 2015, students from Be'er Sheva, associated with Boomerang Therapeutics, won a top prize in Boston's Genetically Engineered Machine Competition.

About

Company Intelligence Q&A

Sectors & technology

Highlights

Tags